Skip to main content
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

G1 Therapeutics, Inc. - Common Stock (NQ:GTHX)

7.150 UNCHANGED
Last Price Updated: 4:00 PM EDT, Sep 17, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about G1 Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 Next >
What 6 Analyst Ratings Have To Say About G1 Therapeutics
 
Via Benzinga
7 Analysts Have This to Say About G1 Therapeutics
 
Via Benzinga
Earnings Scheduled For March 1, 2023
Companies Reporting Before The Bell • Globalstar (AMEX:GSAT) is expected to report quarterly loss at $0.01 per share on revenue of $38.75 million. 
Via Benzinga
G1 Therapeutics Provides Fourth Quarter and Full Year 2022 Financial Results and Operational Highlights
From G1 Therapeutics
Via GlobeNewswire
G1 Therapeutics's Earnings Outlook
 
Via Benzinga
Dow Gains Over 300 Points; S&P 500 Up 1%
U.S. stocks traded higher toward the end of trading, with the Dow Jones gaining over 300 points on Monday. The Dow traded up 1.01% to 34,211.29 while the NASDAQ rose 1.52% to 11,896.33. The S&P 500... 
Via Benzinga
12 Health Care Stocks Moving In Monday's Intraday Session
 
Via Benzinga
G1 Therapeutics Reveals An Early Cut Data From Bladder Cancer Trial
 
Via Benzinga
Why Frequency Therapeutics Are Trading Lower By 82%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Gainers Vallon Pharmaceuticals, Inc. (NASDAQ: VLON) shares jumped 120.5% to $1.02 after jumping over 72% on Friday. 
Via Benzinga
Nasdaq Rises 1.5%; G1 Therapeutics Shares Plummet
U.S. stocks traded higher midway through trading, with the Nasdaq Composite gaining around 1.5% on Monday. The Dow traded up 0.96% to 34,193.83 while the NASDAQ rose 1.52% to 11,896.75. The S&P 500... 
Via Benzinga
Stocks That Hit 52-Week Lows On Monday
  On Monday, 42 companies hit new 52-week lows. 
Via Benzinga
US Stocks Open Higher; Dow Jumps 200 Points
U.S. stocks traded higher this morning, with the Dow Jones gaining around 200 points on Monday. Following the market opening Monday, the Dow traded up 0.59% to 34,069.23 while the NASDAQ rose 0.65% to... 
Via Benzinga
Why Is Monday.com (MNDY) Stock Up 11% Today?
Monday.com (MNDY) stock is on the rise Monday after announcing a partnership with Appfire to expand its app marketplace. 
Via InvestorPlace
NVAX Stock Alert: Novavax Will Provide 1.5 Million More Covid-19 Vaccine Doses to U.S.
Novavax (NVAX) stock is on the move Monday after extending its Covid-19 vaccine supply agreement with the U.S. government. 
Via InvestorPlace
Why Is Sorrento Therapeutics (SRNE) Stock Down 40% Today?
Sorrento Therapeutics (SRNE) stock is falling on Monday after the company filed for bankruptcy alongside Scintilla Pharmaceuticals. 
Via InvestorPlace
Why Is G1 Therapeutics (GTHX) Stock Down 52% Today?
G1 Therapeutics (GTHX) stock is falling on Monday after the company announced plans to discontinue a Phase 3 clinical trial. 
Via InvestorPlace
12 Health Care Stocks Moving In Monday's Pre-Market Session
 
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday
It's time to start the week with a breakdown of the biggest pre-market stock movers traders will want to keep a watch on Monday! 
Via InvestorPlace
G1 Therapeutics Shelves Pivotal Colorectal Trial, After Trilaciclib Triplet Therapy Favored Placebo Arm
 
Via Benzinga
G1 Therapeutics Announces Top Line Results from Pivotal Phase 3 Trial of Trilaciclib in Patients Receiving Triplet Therapy with FOLFOXIRI + Bevacizumab for Metastatic Colorectal Cancer (CRC) (PRESERVE 1)
From G1 Therapeutics
Via GlobeNewswire
Benzinga's Top Ratings Upgrades, Downgrades For January 30, 2023
 
Via Benzinga
G1 Therapeutics Announces Upcoming 2023 Readouts from its Phase 2 and Pivotal Phase 3 Clinical Trials of Trilaciclib
From G1 Therapeutics
Via GlobeNewswire
Initial Results from Phase 2 Mechanism of Action Trial in Early-Stage Triple Negative Breast Cancer Show that a Single Dose of Trilaciclib Favorably Alters the Tumor Microenvironment
From G1 Therapeutics
Via GlobeNewswire
Benzinga's Top Ratings Upgrades, Downgrades For January 5, 2023
 
Via Benzinga
Big Developments Set to be Unveiled at This Year’s San Antonio Breast Cancer Symposium (SABCS)
EQNX::TICKER_START (NASDAQ:ONCY),(NYSE:LLY),(NASDAQ:NEO),(NYSE:ZYME),(NASDAQ:GTHX) EQNX::TICKER_END 
Via FinancialNewsMedia
G1 Therapeutics Announces Closing of Offering of Common Stock
From G1 Therapeutics
Via GlobeNewswire
Nasdaq Down 0.5%; Clearfield Shares Spike Higher
U.S. stocks traded mixed toward the end of trading, with the Nasdaq Composite dropping over 50 points on Friday. 
Via Benzinga
Why InMed Pharmaceuticals Shares Tumbled 28%; Here Are 67 Biggest Movers From Friday
Gainers AGBA Group Holding Limited (NASDAQ: AGBA) gained 50.7% to close at $6.78 on Friday. 
Via Benzinga
12 Health Care Stocks Moving In Friday's Intraday Session
 
Via Benzinga
Why PaxMedica Shares Are Trading Higher By Over 53%? Here Are 47 Stocks Moving In Friday's Mid-Day Session
Gainers PaxMedica, Inc. (NASDAQ: PXMD) gained 53.5% to $2.38 after the company announced an equity investment agreement for up to $20 million with Lincoln Park Capital. 
Via Benzinga
< Previous 1 2 3 4 5 6 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.